MedTrace Logo

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

NCT06915766 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who have received and failed or been intolerant to at least one standard approved therapy and/or have no comparable or satisfactory alternative therapy options.

Conditions

  • Systemic Mastocytoses, Indolent
  • Systemic Mastocytoses, Aggressive

Interventions

DRUG

Bezuclastinib

Drug: Bezuclastinib Tablets

Sponsors & Collaborators

  • Cogent Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Rachael Easton, MD, PhD · Cogent Biosciences, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06915766 on ClinicalTrials.gov